Reading the tape
NYSE: BMY
Bristol-Myers Squibb Company
Healthcare · Drug Manufacturers - General
Market Cap
$114.68B
52w High
$62.89
52w Low
$42.52
P/E
15.78
Volume
9.96M
Outstanding Shares
2.04B
Valuation Data Insufficient
The DCF model's fair value estimate is more than 3× the current stock price. This typically indicates unreliable model inputs — such as irregular cash flows or balance sheet distortions — rather than a genuine opportunity, so the valuation is not shown.
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
1Y Price: 19.8%Revenue (TTM): 1.78%FCF (TTM): -9%P/FCF: 28th pct
What changed
The stock rose 19.8% over the last year. Revenue grew 1.78% over the trailing twelve months. Operating margin moved from 22.93% to 25.67%. Free cash flow declined 9% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 25.67%. A decisive move in revenue — currently up 1.78% — would be the clearest signal to resolve the ambiguity.
Company profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide.
CEOChristopher S. Boerner
SectorHealthcare
IndustryDrug Manufacturers - General
Employees34,100
IPO dateJun 1, 1972
Valuation
Forward P/E—
EV/EBITDA10.11
Enterprise value$147.02B
Stock splits
Aug 7, 2001↑ Forward
Every 951777 shares became 1000000
Mar 1, 1999↑ Forward
Every 1 shares became 2
Mar 3, 1997↑ Forward
Every 1 shares became 2
Jun 10, 1987↑ Forward
Every 1 shares became 2
May 27, 1983↑ Forward
Every 1 shares became 2
May 31, 1977↑ Forward
Every 1 shares became 2
Profitability & growth
Revenue growth2.57%
Gross margin68.75%▲19.11%vs FY2024
Operating margin25.67%▲31.74%vs FY2024
ROE38.18%▲169.70%vs FY2024
Analyst consensus
RatingHold
Target price$62.00▲10.40%
19
Buy
20
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Jul 30, 2026
Q3 FY26 · EPS est $1.63 · Revenue est $11.72B
View
Dividends
$2.50/shareQuarterly4yr growth streakAdequateBMY pays a dividend with a 4.45% dividend yield, 4 consecutive years of growth, growing at 1.61% annually, covered 2.5× by free cash flow.
Dividend Yield
4.45%
Annual Div / Share
$2.50
5yr CAGR
+1.61%
Doubles every ~43.5yr
Payout Ratio
69.69%
Adequate
Dividend Growth Rate
3yr CAGR
+4.71%
5yr CAGR
+1.61%
10yr CAGR
+5.23%
Dividend Safety
7/10Adequate
Dividend History
Annual dividends paid per share
YearAnnual DivYoY
2025$2.48+3.3%
2024$2.40+5.3%
2023$2.28+5.6%
2022$2.16+46.9%
2021$1.47-35.8%
2020$2.29+39.6%
2019$1.64+2.5%
Income Projection
Invest
$
Growth rate:
Reinvest dividends
Today
$45/yr
$4/mo
In 5 yrs
$48/yr+8%
$4/mo
In 10 yrs
$52/yr+17%
$4/mo
| Today | In 5 yrs | In 10 yrs |
|---|---|---|
$45/yr $4/mo | $48/yr+8% $4/mo | $52/yr+17% $4/mo |
Yield-on-cost grows from 4.45% → 5.22% over 10yr
Analysis
Dividend Strengths
Well-covered by free cash flow
The dividend is covered 2.5× by free cash flow, indicating the company generates sufficient cash to sustain and potentially grow the payout without straining its finances.
Risks to Watch
No strong risk signal stands out from the latest period pair.